Immune Checkpoint Inhibitors Market Size, Share, and Trends 2024 to 2034

The global immune checkpoint inhibitors market size accounted for USD 58.53 billion in 2025 and is predicted to surpass around USD 229.60 billion by 2034, representing a healthy CAGR of 16.40% between 2025 and 2034. The North America immune checkpoint inhibitors market size was calculated at USD 23.63 billion in 2024 and is expected to grow at a fastest CAGR of 16.42% during the forecast year. The market sizing and forecasts are revenue-based (USD Million/Billion), with 2024 as the base year.

  • Last Updated : May 2025
  • Report Code : 2281
  • Category : Healthcare

Chapter 1. Introduction

1.1. Research Objective

1.2. Scope of the Study

1.3. Definition

Chapter 2. Research Methodology

2.1. Research Approach

2.2. Data Sources

2.3. Assumptions & Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Market Variables and Scope 

4.1. Introduction

4.2. Market Classification and Scope

4.3. Industry Value Chain Analysis

4.3.1. Raw Material Procurement Analysis 

4.3.2. Sales and Distribution Channel Analysis

4.3.3. Downstream Buyer Analysis

Chapter 5. COVID 19 Impact on Immune Checkpoint Inhibitors Market 

5.1. COVID-19 Landscape: Immune Checkpoint Inhibitors Industry Impact

5.2. COVID 19 - Impact Assessment for the Industry

5.3. COVID 19 Impact: Global Major Government Policy

5.4. Market Trends and Opportunities in the COVID-19 Landscape

6.1. Market Dynamics

6.1.1. Market Drivers

6.1.2. Market Restraints

6.1.3. Market Opportunities

6.2. Porter’s Five Forces Analysis

6.2.1. Bargaining power of suppliers

6.2.2. Bargaining power of buyers

6.2.3. Threat of substitute

6.2.4. Threat of new entrants

6.2.5. Degree of competition

Chapter 7. Competitive Landscape

7.1.1. Company Market Share/Positioning Analysis

7.1.2. Key Strategies Adopted by Players

7.1.3. Vendor Landscape

7.1.3.1. List of Suppliers

7.1.3.2. List of Buyers

Chapter 8. Global Immune Checkpoint Inhibitors Market, By Drug Type

8.1. Immune Checkpoint Inhibitors Market, by Drug Type

8.1.1 CTLA-4 Inhibitor

8.1.1.1. Market Revenue and Forecast

8.1.2. PD-1 Inhibitor

8.1.2.1. Market Revenue and Forecast

8.1.3. PD-L1 Inhibitor

8.1.3.1. Market Revenue and Forecast

Chapter 9. Global Immune Checkpoint Inhibitors Market, By Disease Indication

9.1. Immune Checkpoint Inhibitors Market, by Disease Indication

9.1.1. Lung Cancer

9.1.1.1. Market Revenue and Forecast

9.1.2. Bladder Cancer

9.1.2.1. Market Revenue and Forecast

9.1.3. Melanoma

9.1.3.1. Market Revenue and Forecast

9.1.4. Hodgkin lymphoma

9.1.4.1. Market Revenue and Forecast

9.1.5. Others

9.1.5.1. Market Revenue and Forecast

Chapter 10. Global Immune Checkpoint Inhibitors Market, By End-Users 

10.1. Immune Checkpoint Inhibitors Market, by End-Users

10.1.1. Hospitals

10.1.1.1. Market Revenue and Forecast

10.1.2. Specialty Clinics

10.1.2.1. Market Revenue and Forecast

10.1.3. Academic & Research Institutions

10.1.3.1. Market Revenue and Forecast

Chapter 11. Global Immune Checkpoint Inhibitors Market, Regional Estimates and Trend Forecast

11.1. North America

11.1.1. Market Revenue and Forecast, by Drug Type

11.1.2. Market Revenue and Forecast, by Disease Indication

11.1.3. Market Revenue and Forecast, by End-Users

11.1.4. U.S.

11.1.4.1. Market Revenue and Forecast, by Drug Type

11.1.4.2. Market Revenue and Forecast, by Disease Indication

11.1.4.3. Market Revenue and Forecast, by End-Users

11.1.5. Rest of North America

11.1.5.1. Market Revenue and Forecast, by Drug Type

11.1.5.2. Market Revenue and Forecast, by Disease Indication

11.1.5.3. Market Revenue and Forecast, by End-Users

11.2. Europe

11.2.1. Market Revenue and Forecast, by Drug Type

11.2.2. Market Revenue and Forecast, by Disease Indication

11.2.3. Market Revenue and Forecast, by End-Users

11.2.4. UK

11.2.4.1. Market Revenue and Forecast, by Drug Type

11.2.4.2. Market Revenue and Forecast, by Disease Indication

11.2.4.3. Market Revenue and Forecast, by End-Users

11.2.5. Germany

11.2.5.1. Market Revenue and Forecast, by Drug Type

11.2.5.2. Market Revenue and Forecast, by Disease Indication

11.2.5.3. Market Revenue and Forecast, by End-Users

11.2.6. France

11.2.6.1. Market Revenue and Forecast, by Drug Type

11.2.6.2. Market Revenue and Forecast, by Disease Indication

11.2.6.3. Market Revenue and Forecast, by End-Users

11.2.7. Rest of Europe

11.2.7.1. Market Revenue and Forecast, by Drug Type

11.2.7.2. Market Revenue and Forecast, by Disease Indication

11.2.7.3. Market Revenue and Forecast, by End-Users

11.3. APAC

11.3.1. Market Revenue and Forecast, by Drug Type

11.3.2. Market Revenue and Forecast, by Disease Indication

11.3.3. Market Revenue and Forecast, by End-Users

11.3.4. India

11.3.4.1. Market Revenue and Forecast, by Drug Type

11.3.4.2. Market Revenue and Forecast, by Disease Indication

11.3.4.3. Market Revenue and Forecast, by End-Users

11.3.5. China

11.3.5.1. Market Revenue and Forecast, by Drug Type

11.3.5.2. Market Revenue and Forecast, by Disease Indication

11.3.5.3. Market Revenue and Forecast, by End-Users

11.3.6. Japan

11.3.6.1. Market Revenue and Forecast, by Drug Type

11.3.6.2. Market Revenue and Forecast, by Disease Indication

11.3.6.3. Market Revenue and Forecast, by End-Users

11.3.7. Rest of APAC

11.3.7.1. Market Revenue and Forecast, by Drug Type

11.3.7.2. Market Revenue and Forecast, by Disease Indication

11.3.7.3. Market Revenue and Forecast, by End-Users

11.4. MEA

11.4.1. Market Revenue and Forecast, by Drug Type

11.4.2. Market Revenue and Forecast, by Disease Indication

11.4.3. Market Revenue and Forecast, by End-Users

11.4.4. GCC

11.4.4.1. Market Revenue and Forecast, by Drug Type

11.4.4.2. Market Revenue and Forecast, by Disease Indication

11.4.4.3. Market Revenue and Forecast, by End-Users

11.4.5. North Africa

11.4.5.1. Market Revenue and Forecast, by Drug Type

11.4.5.2. Market Revenue and Forecast, by Disease Indication

11.4.5.3. Market Revenue and Forecast, by End-Users

11.4.6. South Africa

11.4.6.1. Market Revenue and Forecast, by Drug Type

11.4.6.2. Market Revenue and Forecast, by Disease Indication

11.4.6.3. Market Revenue and Forecast, by End-Users

11.4.7. Rest of MEA

11.4.7.1. Market Revenue and Forecast, by Drug Type

11.4.7.2. Market Revenue and Forecast, by Disease Indication

11.4.7.3. Market Revenue and Forecast, by End-Users

11.5. Latin America

11.5.1. Market Revenue and Forecast, by Drug Type

11.5.2. Market Revenue and Forecast, by Disease Indication

11.5.3. Market Revenue and Forecast, by End-Users

11.5.4. Brazil

11.5.4.1. Market Revenue and Forecast, by Drug Type

11.5.4.2. Market Revenue and Forecast, by Disease Indication

11.5.4.3. Market Revenue and Forecast, by End-Users

11.5.5. Rest of LATAM

11.5.5.1. Market Revenue and Forecast, by Drug Type

11.5.5.2. Market Revenue and Forecast, by Disease Indication

11.5.5.3. Market Revenue and Forecast, by End-Users

Chapter 12. Company Profiles

12.1. AstraZeneca PLC

12.1.1. Company Overview

12.1.2. Product Offerings

12.1.3. Financial Performance

12.1.4. Recent Initiatives

12.2. Bristol-Myers Squibb Company

12.2.1. Company Overview

12.2.2. Product Offerings

12.2.3. Financial Performance

12.2.4. Recent Initiatives

12.3. Eli Lilly and Company (ARMO Biosciences.)

12.3.1. Company Overview

12.3.2. Product Offerings

12.3.3. Financial Performance

12.3.4. Recent Initiatives

12.4. GlaxoSmithKline PLC

12.4.1. Company Overview

12.4.2. Product Offerings

12.4.3. Financial Performance

12.4.4. Recent Initiatives

12.5. Roche Holding AG

12.5.1. Company Overview

12.5.2. Product Offerings

12.5.3. Financial Performance

12.5.4. Recent Initiatives

12.6. Incyte Corporation

12.6.1. Company Overview

12.6.2. Product Offerings

12.6.3. Financial Performance

12.6.4. Recent Initiatives

12.7. Novartis AG

12.7.1. Company Overview

12.7.2. Product Offerings

12.7.3. Financial Performance

12.7.4. Recent Initiatives

12.8. F. Hoffmann-La Roche Ltd. (Genentech Inc.,)

12.8.1. Company Overview

12.8.2. Product Offerings

12.8.3. Financial Performance

12.8.4. Recent Initiatives

12.9. Sanofi, Merck & Co., Inc.

12.9.1. Company Overview

12.9.2. Product Offerings

12.9.3. Financial Performance

12.9.4. Recent Initiatives

12.10. Merck KGaA (EMD Serono Inc.)

12.10.1. Company Overview

12.10.2. Product Offerings

12.10.3. Financial Performance

12.10.4. Recent Initiatives

Chapter 13. Research Methodology

13.1. Primary Research

13.2. Secondary Research

13.3. Assumptions

Chapter 14. Appendix

14.1. About Us

14.2. Glossary of Terms

For questions or customization requests, please reach out to us at sales@precedenceresearch.com

Frequently Asked Questions

The global immune checkpoint inhibitors market size was accounted at USD 50.28 billion in 2024 and it is expected to reach around USD 229.60 billion by 2034.

The global immune checkpoint inhibitors market is poised to grow at a CAGR of 16.40% from 2025 to 2034.

The major players operating in the immune checkpoint inhibitors market are AstraZeneca PLC, Bristol-Myers Squibb Company, Eli Lilly and Company (ARMO Biosciences.), GlaxoSmithKline PLC, Roche Holding AG, Incyte Corporation, Novartis AG, F. Hoffmann-La Roche Ltd. (Genentech Inc.,), Sanofi, Merck & Co., Inc., Merck KGaA (EMD Serono Inc.), BeiGene Ltd, Shanghai Jhunsi Biosciences Ltd.

Technological advancement in screening & diagnosis of cancer, rise in prevalence of cancer, increase in government initiatives and high cost associated with the R & D these are driving the growth of the immune checkpoint inhibitors market.

North America region will lead the global immune checkpoint inhibitors market during the forecast period 2025 to 2034.

Ask For Sample

No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client